Table 1 Approved immunotherapies for cancer treatment
From: Delivery strategies of cancer immunotherapy: recent advances and future perspectives
Class | Agent | Description | Indications |
|---|---|---|---|
Cytokines | Intron A | Recombinant IFNα2b | Hairy cell leukemia, melanoma, follicular lymphoma, and AIDS-related Kaposi sarcoma |
Roferon-A | Recombinant IFNα2a | Hairy cell leukemia, chronic myelogenous leukemia, and AIDS-related Kaposi sarcoma | |
Aldesleukin | Recombinant IL-2 | Melanoma and kidney cancer | |
Imiquimod | Stimulating TNF, IL-12, and IFNγ production | Basal cell carcinoma | |
Cancer vaccines | Sipuleucel-T | Autologous PBMCs activated with recombinant human PAP–GM-CSF | Prostate cancer |
Bacillus Calmette–Guérin | Strain of Mycobacterium tuberculosis variant bovis | Bladder cancer | |
Immune checkpoint inhibitors | Ipilimumab | CTLA-4 mAb | Melanoma |
Pembrolizumab | PD-1 mAb | Melanoma, non-small-cell lung cancer, Hodgkin lymphoma, advanced gastric cancer, microsatellite instability-high cancer, head and neck cancer, and advanced urothelial bladder cancer | |
Nivolumab | Melanoma, bladder cancer, classical Hodgkin lymphoma, colorectal cancer, hepatocellular cancer, non-small-cell lung cancer, kidney cancer, squamous cell carcinoma of the head and neck, and urothelial cancer | ||
Atezolizumab | PD-L1 mAb | Urothelial cancer and non-small-cell lung cancer | |
Avelumab | Merkel cell carcinoma and urothelial cancer | ||
Durvalumab | Urothelial cancer and non-small-cell lung cancer | ||
CAR-T cells | Tisagenlecleucel | CD19-specific CAR-T cells | B cell acute lymphocytic leukemia and non-Hodgkin lymphoma |
Axicabtagene ciloleucel | Large B cell lymphoma |